First Time Loading...

Amryt Pharma Holdings Ltd
LSE:AMYT

Watchlist Manager
Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd
LSE:AMYT
Watchlist
Price: 143 GBX -11.73%
Updated: May 7, 2024

Amryt Pharma Holdings Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amryt Pharma Holdings Ltd
Net Income (Common) Peer Comparison

Comparables:
GSK
AZN
INDV
HIK
DPH

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Amryt Pharma Holdings Ltd
LSE:AMYT
Net Income (Common)
-$104.5m
CAGR 3-Years
-51%
CAGR 5-Years
-103%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Net Income (Common)
£4.5B
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
-1%
AstraZeneca PLC
LSE:AZN
Net Income (Common)
$6.3B
CAGR 3-Years
17%
CAGR 5-Years
21%
CAGR 10-Years
12%
Indivior PLC
LSE:INDV
Net Income (Common)
$5m
CAGR 3-Years
-63%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Net Income (Common)
$190m
CAGR 3-Years
-24%
CAGR 5-Years
-8%
CAGR 10-Years
-1%
Dechra Pharmaceuticals PLC
LSE:DPH
Net Income (Common)
-£27.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Amryt Pharma Holdings Ltd's Net Income (Common)?
Net Income (Common)
-104.5m USD

Based on the financial report for Dec 31, 2020, Amryt Pharma Holdings Ltd's Net Income (Common) amounts to -104.5m USD.

What is Amryt Pharma Holdings Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-103%

Over the last year, the Net Income (Common) growth was -66%. The average annual Net Income (Common) growth rates for Amryt Pharma Holdings Ltd have been -51% over the past three years , -103% over the past five years .